Patients with GCK heterozygous mutations present progressive β-cell dysfunction, fasting hyperglycemia and reduced insulin secretion. These result in a mild diabetes phenotype that generally does not require anti-diabetes medication. This evidence concerns the gene INS and diabetes mellitus.